Skip to content

D&A at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$6.84M+28.3%
Absci Corporation logo
Absci CorporationABSI
$2.73M-11.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.4%
XER
Xeris Biopharma Holdings, Inc.XERS
$2.71M0.0%
Amgen logo
AmgenAMGN
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's D&A?
Xencor (XNCR) reported D&A of $2.57M in Q1 2026.
How has Xencor's D&A changed year-over-year?
Xencor's D&A decreased by 4.7% year-over-year, from $2.69M to $2.57M.
What is the long-term trend for Xencor's D&A?
Over 4 years (2021 to 2025), Xencor's D&A has grown at a 8.8% compound annual growth rate (CAGR), from $7.49M to $10.51M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.